Authors: Jie Guan Yao Deng Hong Chen Xiao Yin Yang Yang Wenjie Tan
Publish Date: 2015/07/28
Volume: 160, Issue: 10, Pages: 2517-2524
Abstract
Development an effective vaccine may offer an alternative preventive and therapeutic strategy against HCV infection DNA vaccination has been shown to induce robust humoral and cellular immunity and overcome many problems associated with conventional vaccines In this study mice were primed with either conventional pVRCbased or suicidal pSCbased DNA vaccines carrying DEC205targeted NS3 antigen DECNS3 and boosted with type 5 adenoviral vectors encoding the partial NS3 and core antigens C44P The prime boost regimen induced a marked increase in antigenspecific humoral and Tcell responses in comparison with either rAd5based vaccines or DEC205targeted DNA immunization in isolation The protective effect against heterogeneous challenge was correlated with high levels of antiNS3 IgG and Tcellmediated immunity against NS3 peptides Moreover priming with a suicidal DNA vaccine pSCDECNS3 which elicited increased TNFαproducing CD4+ and CD8+ Tcells against NS32 peptides aa 1245–1461 after boosting showed increased heterogeneous protective potential compared with priming with a conventional DNA vaccine pVRCDECNS3 In conclusion a suicidal DNA vector pSCDECNS3 expressing DEC205targeted NS3 combined with boosting using an rAd5based HCV vaccine rAd5C44P is a good candidate for a safe and effective vaccine against HCV infectionThe authors thank Dr Gary Nabel VRC NIH USA for providing the pVRC vector Dr Rod Bremner University of Toronto Canada for providing the pSC vector and Dr RM Steinman The Rockefeller University USA for providing the DEC205 plasmid This study was supported by the 863 HiTech Research and Development Program of China 2007AA02Z455 and the National Natural Science Foundation of China 81373229
Keywords: